The US Federal Trade Commission is reportedly seeking $1 billion for so-called pay-for-delay schemes.
The FTC said at a conference that the damages are being sought from pharmaceutical companies being sued by the regulator for paying generic rivals to delay the release of their cheaper competition onto the market. The US Supreme Court ruled last June that the FTC could challenge such agreements in federal court.
The remarks were made by FTC’s Deborah Feinstein, the regulators director at the Bureau of Competition, at the American Bar Association’s spring meeting.
My hope is that we get a billion-dollar settlement in tone of the patent-settlement, pay-for-delay cases,” she said in reference to developments for the authority this year.
While no such settlement is expected in the immediate future, Feinstein said that pay-for-delay schemes are “one of the biggest priorities” for the FTC.
The FTC is currently pursuing cases against Solvay, Paddock Laboratories, and Teva-owned Cephalon, according to reports.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Regulator Proposes State-Backed Formula to Lower Baby Formula Costs
Nov 10, 2024 by
CPI
Justice Department Probes Alleged Price-Fixing in PVC Pipe Industry
Nov 10, 2024 by
CPI
US Imposes Ban on TSMC’s Advanced Chip Exports to China Amid AI Concerns
Nov 10, 2024 by
CPI
Vanderbilt QB Sues NCAA Over Junior College Eligibility Rules
Nov 10, 2024 by
CPI
Trump’s Transition Team Prepares to Reshape FTC Leadership and Antitrust Agenda
Nov 10, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI